TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 90-day major adverse neurological event (MANE)
Endpoint domain: Mortality/survival
Primary endpoint: Change in retroversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pressure required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to BIS <50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-operative infections
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in inhaled beta 2‐agonist use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exercise cardiac index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: exercise systolic arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Breast size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: incidence of loose/watery stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean number of loose/watery stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of abdominal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: non-HDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DRS‐R98 severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMSE scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: digoxin area under the plasma concentration‐time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: digoxin clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: digoxin terminal half‐life in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good recovery (GOS score 5)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Moderate disability (GOS score 4)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plasma histamine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICU admission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient requirements for rescue medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Increase in serum specific IgG4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in asthma development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Flow‐mediated dilation of the brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: flow velocity in the middle cerebral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Peak and AUC of total stimulation scale score after alcohol intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak and AUC of total sedation scale score after alcohol intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for BAC in males
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid peroxidation (MDA levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Volume reduction after 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported measures of self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complete success rate of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of wet nights by more than 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Esophageal pressure variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Esophageal pressure-time product/min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Work of breathing/min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total negative work at the ankle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of hyperstimulation syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: TIMI flow grade 3 frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: residual percent stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: minimal lumen diameter of the infarct-related artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PSG total sleep time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NREM sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Awakenings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Promotion of sexual health among FE students
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days with illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of days with respiratory illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: patient assessment of disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional parameters improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in glabellar lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic concordance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the approach
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the approach
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activated Clotting Time (ACT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGTC seizure frequency per 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: 50% PGTC seizure responder rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: PGTC seizure freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Acceptance of VCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timeliness of antiretroviral prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative blood effluents and transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hematocrit improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Dizziness Handicap Inventory total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: standing on one leg eyes open
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blindfolded tandem stance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of propofol-induced pain
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of propofol-induced pain
Endpoint domain: Adverse events/effects
Primary endpoint: Cheek cell fatty acids as a marker of essential fatty acid content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: severity of depression and anxiety at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse reactions (bradycardia, atrial fibrillation, heart failure)
Endpoint domain: Adverse events/effects
Primary endpoint: Development of BPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change of BGP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change of total body BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change of radio distal 1/3 BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median reduction of HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median alanine aminotransferase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BCG response rate
Endpoint domain: Mortality/survival
Primary endpoint: Minimum voided volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle atrophy of the thigh muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: One leg hop test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean stool frequency change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in ST-segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neck strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total time in the hospital after surgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: plasma hepcidin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: macular sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: macular blood flow change ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated cost per activity
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Median time to treatment failure (TTF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hours of oxygen therapy needed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Titratable acidity values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-reducing sugars values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Fever rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: residual tumor vascularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: incidence of adult respiratory distress syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Primary TB score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total dose of opioids during the operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS scores at 4 and 6 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICU stay and hospital stay after surgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Severity of breakthrough pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain-induced physical and emotional dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean induction-abortion intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for administration route
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Average blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary intracranial hemorrhage rates
Endpoint domain: Mortality/survival
Primary endpoint: Time from meeting inclusion criteria to randomization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from meeting inclusion criteria to study drug administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biphasic thyroiditis incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Hypothyroidism incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Abnormal TSH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: FT specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: sleep disturbance reduction
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Clinical adequacy of colonic distention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AHA score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial grimacing scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global charges
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Complete ablation of thyroid remnant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: spontaneous growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insulin sensitivity (IS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: blood flow in the whole hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for additional bronchoscopic procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean puncture number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Acute myocardial infarction diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mattis Dementia Rating Scale Memory subscale performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Urinary excretion of niacin metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean cerebrospinal fluid glycosaminoglycan concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of CAL gain ≥4 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of residual PD ≥6 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of diabetic foot ulcers (DFU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary function improvement (FEV1, FVC, RV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in dyspnoea (Borg score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma BuChE activity <600 mU/ml on admission
Endpoint domain: Mortality/survival
Primary endpoint: Change in score in the perceived motor competence scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CapBG reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: behavioral intent to engage in detection behaviors
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reduction in hunger sensations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in total caloric intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in sweet snack intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time for re-epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scar quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum OPN levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death or unplanned hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Quality-of-life changes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mean 24-hour posttransfusion recovery of S-303 RBCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: median life span of S-303 RBCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Average canal compromise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average fracture kyphosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability reported at final follow-up
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reliable P(CO2) measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeat hospitalization rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Repeat revascularization rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of time plasma glucose below 4.0 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of hypoglycemic events (<3.0 mmol/L)
Endpoint domain: Adverse events/effects
Primary endpoint: ocular health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: continuous abstinence rate at 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: point prevalence abstinence rate at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cure Rate (CR) against T. trichiura
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Egg Reduction Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to defervescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median time to symptomatic remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean endocardial segment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of recorded medical appointments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cardiac related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate of surgical site infections
Endpoint domain: Adverse events/effects
Primary endpoint: rate of postoperative infection complications
Endpoint domain: Adverse events/effects
Primary endpoint: Poor sleep efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enlarged BG-PVS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum total point motion (MTPM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in SF-MPQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates to hepatitis B vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prosthodontic maintenance efforts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Major prosthetic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Responder rates for depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: airway eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: FLS severity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED(50) level of P(ET)-sevoflurane for LMA insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED(50) level of propofol for LMA insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal continuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enamel fractures
Endpoint domain: Adverse events/effects
Primary endpoint: maintenance of happiness levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sustained weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: composite of death or reinfarction
Endpoint domain: Mortality/survival
Primary endpoint: Concentration of amikacin in blister fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance of bowel preparation
Endpoint domain: Adverse events/effects
Primary endpoint: Fecal incontinence
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement on the CGI-I scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement on the CY-BOCS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the NIMH GOCS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes